Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function.

Cancer immunology research·2026
Same author

Takotsubo Syndrome Presenting as ST-Elevation Myocardial Infarction With Concomitant Persistent High-Grade AV Block Requiring Cardiac Resynchronisation Therapy Pacemaker.

Case reports in cardiology·2026
Same author

Apical Hypertrophic Cardiomyopathy: A Rare and Hidden Cause of Stroke.

Cureus·2025
Same author

Mycotic Hepatic Artery Aneurysm in Staphylococcus aureus Infective Endocarditis.

Cureus·2025
Same author

Transthyretin-Related Cardiac Amyloidosis: A Case of Delayed Diagnosis in the Comorbid Patient and Literature Review.

Cureus·2025
Same author

Role of Artificial Intelligence in Reducing Data Deluge From Cardiac Implantable Electronic Devices.

JACC. Advances·2025

Related Experiment Video

Updated: Nov 3, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.9K

CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.

Caitlin E Egan1, Dessislava Stefanova1, Adnan Ahmed2

  • 1Department of Surgery, Weill Cornell Medicine, New York, New York, USA.

Thyroid : Official Journal of the American Thyroid Association
|June 3, 2021
PubMed
Summary

Chondroitin sulfate-proteoglycan-4 (CSPG4) is highly expressed in aggressive thyroid cancers, presenting a promising new target for immunotherapy. Its elevated presence correlates with poor prognosis and tumor aggressiveness.

Keywords:
CSPG4anaplastic thyroid cancerthyroid cancer

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.3K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.0K

Related Experiment Videos

Last Updated: Nov 3, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.9K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.3K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.0K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Anaplastic thyroid cancer (ATC) is aggressive with limited treatment options.
  • Identifying novel immune targets is crucial for improving ATC therapy.
  • Chondroitin sulfate-proteoglycan-4 (CSPG4) is implicated in aggressive cancers but unstudied in ATC.

Purpose of the Study:

  • To investigate CSPG4 as a potential immunotherapeutic target in ATC.
  • To identify and characterize ATC-derived, human leukocyte antigen (HLA) class II-presenting peptides.
  • To analyze CSPG4 expression in thyroid cancer and its correlation with clinicopathological features.

Main Methods:

  • Tumor-specific T cell response assessment in patient-derived xenografted mice.
  • Mass spectrometry to identify peptide antigens eluted from the HLA-DQ complex.
  • Flow cytometry and immunohistochemistry to analyze CSPG4 expression in thyroid cancer tissues and cell lines.

Main Results:

  • ATC tissues exhibit high HLA-DQ expression and induce CD4+ T cell activation.
  • CSPG4 was identified as a highly abundant and specific peptide eluted from the HLA-DQ complex in ATC.
  • Significantly elevated CSPG4 expression was observed on the cell surface of thyroid cancer cells, particularly ATC, correlating with tumor size, extrathyroidal extension, and poorer survival.

Conclusions:

  • CSPG4 is significantly upregulated in aggressive thyroid cancers and correlates with poor prognosis.
  • Abundant CSPG4-derived peptides presented by HLA-DQ in ATC highlight its potential as a novel immunotherapeutic target.
  • Targeting CSPG4 may offer a new avenue for treating anaplastic thyroid cancer.